spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

HemaCare and Tissue Solutions Announce Strategic Partnership to Expand Access to Human Disease-State Samples

Advancing discoveries by providing scientists with high-quality disease-state biospecimens to support preclinical and clinical research

HemaCare Corporation (OTCMKTS: HEMA), a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development, and Tissue Solutions Ltd, a leading global provider of diseased human biosamples for research, today announced their partnership to supply customers with an expanded selection of well-qualified disease-state biomaterials in fresh, frozen, and FFPE formats.

Access to patient-donor material is an immense challenge researchers and pharmaceutical companies face when sourcing human starting material. As a therapy or drug moves through research and development to commercialization, the need for donor samples that meet specific disease criteria increases as it offers the closest approximation of real-life cellular responses.

Partnering with Tissue Solutions will allow HemaCare to further meet growing market needs by expanding its current disease-state product portfolio. HemaCare customers will now have access to pathology-verified frozen and FFPE tissues, as well as hard-to-source disease samples such as tumor tissues and dissociated tumor cells isolated from freshly resected tumors.

“HemaCare has seen a high demand from scientists and clinical researchers for blood and other tissue samples from diseased patients,” said Lou Juliano, HemaCare’s SVP of Global Sales and Business Development. “Tissue Solutions is already one of HemaCare’s preferred European distributors and this expanded partnership allows our customers to readily access over 110 million banked human samples sourced through a network of more than 500 qualified suppliers.”

Commitment to supporting scientists is a chief priority for HemaCare and Tissue Solutions. By partnering to expand the disease-state product offerings, researchers will be able to access well-characterized disease-state starting material within a short turnaround time. With faster access to such material, a researcher can accelerate their research timelines and focus on curing human disease.

“We are delighted to expand our partnership with HemaCare as their commitment to quality has always been the best in the industry,”
said Morag McFarlane, Ph.D., Tissue Solutions’ Chief Executive Officer. “HemaCare is our preferred apheresis provider and we utilize their extensive donor database for a majority of customer requests. The expanded partnership will help provide HemaCare’s customers with a broadened portfolio of well-qualified disease tissues and normal adjacent tissue or matched tumor tissue from the same donor where necessary.”

HemaCare’s expanded biospecimen portfolio can be found here. For general information about products visit HemaCare’s website at www.hemacare.com.

For more information about Tissue Solutions please visit www.tissue-solutions.com.

 

About HemaCare

HemaCare is a global leader in the customization of human-derived biological products and services for biomedical research, drug discovery and cellular therapy process development. The company’s network of FDA-registered, GMP/GTP-compliant collection centers ensure fresh donor material is available to customers and for use within HemaCare’s isolation laboratory. Human biological material including peripheral blood, bone marrow, and cord blood is isolated into various primary cells types for fresh and frozen distribution. For over 40 years, HemaCare has developed an extensive registry of repeat donors and provides human-derived primary blood cells and tissues for biomedical and drug discovery research and cell therapy clinical trials, and supports commercialization with apheresis collections, directly enabling customers to advance both autologous and allogeneic cellular therapies.

 

About Tissue Solutions

Tissue Solutions is a customer-focused global provider of ethically sourced human samples required for preclinical drug development and research. The ISO 9001 (2015) accredited company provides a tissue provision service through a global network to individual requirements ensuring projects are not constrained by access to human biomaterials or collection timelines. Tissue Solutions also offers a comprehensive integrated range of tissue related GLP/GCP compliant IHC and Histology services, offering a single access point for pre-clinical and clinical research. Services include sourcing difficult to obtain samples for a range of applications such as target identification and validation, biomarker studies, companion diagnostics, pharmacogenetics and safety testing. They specialize in sourcing “tough” tissues, e.g. fresh samples, skin biopsies. The management team has a wealth of experience gained from many years in the biotech and pharmaceutical industry with expertise on ethics and compliance, and logistics.

 

Media Contacts:

HemaCare
Maria Thompson
619-722-0970

Tissue Solutions
Fiona Mackenzie
0141 299 0055
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Aptar Pharma Co Organizer and Diamond Sponsor of RDD Europe 2019 Conference in Estoril Portugal

Crystal Lake, Illinois, March 21, 2019 Aptar Pharma, the leader in respiratory drug delivery systems, is proud to announce its coorganization and diamond sponsorship of the Respiratory Drug Delivery (RDD®) Europe 2019 scientific conference, connecting pulmonary and nasal drug delivery experts from around the world in Estoril, Portugal from May 7-10, 2019.
More info >>


White Papers

Pharmacovigilance and Risk Management Information in Centralised Applications in the EU

United BioSource Corporation (UBC)

Getting a new medication approved for the EU market through the centralised procedure can be complex and needs expertise. The new EU pharmacovigilance legislation (Good Vigilance Practice, GVP) is now in effect and applicants need to be fully compliant. It is critical to have a thorough understanding of the regulatory process and requirements, and the expectations with regards to the pharmacovigilance system and the risk management plan. Ensuring consistency and an appropriate level of detail in the documentation submitted as part of the approval process will help prevent unnecessary delays.
More info >>

Industry Events

Highly Potent Active Pharmaceutical Ingredients (HPAPI)

13-14 May 2019, Copthorne Tara Hotel, London, UK

SMi is delighted to announce its 3rd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 13th-14th May 2019. The HPAPI global market has developed rapidly in the past year and is continuing to expand into the future, with over a quarter of drugs in development worldwide being classified as highly potent. As a result, there is a growing demand for both pharmaceutical and contracted manufacturers to adapt to the evolving HPAPI landscape.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement